Ifeanyichukwu Anusionwu, MD
Payments from drug & device makers
Across 45 payments — averaging $82.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$2K
- Neotract Inc.$596
- Axonics, Inc.$363
- Medtronic$89
- 180 Medical, Inc.$62
- Olympus America Inc.$45
- plus $120 from 6 others
What the payments were for
- Consulting fees$481%
- Travel & lodging$2,18459%
- Food & beverage$1,47240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 17 | $2,431 |
| Neotract Inc. | 2 | $596 |
| Axonics, Inc. | 10 | $363 |
| Medtronic | 4 | $89 |
| 180 Medical, Inc. | 3 | $62 |
| Olympus America Inc. | 2 | $45 |
| Convatec Inc. | 2 | $42 |
| Immunitybio, Inc. | 1 | $24 |
| Dendreon Pharmaceuticals LLC | 1 | $15 |
| Civco Medical Instruments | 1 | $15 |
| Endo Pharmaceuticals Inc. | 1 | $13 |
| Agiliti Surgical, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,704 in reported general payments places this provider in the 50th percentile of 878 urology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 93 | $55,894 |
| MyrbetriqMirabegron | 15 | $12,356 |
| Cefdinir | 101 | $1,314 |
| Tamsulosin Hcl | 140 | $1,274 |
| Solifenacin Succinate | 27 | $748 |
| Estradiol | 16 | $718 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 29 | $658 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 61 | $432 |
| Finasteride | 35 | $323 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 15 | $276 |
| Testosterone Cypionate | 13 | $267 |
| Ciprofloxacin Hcl | 18 | $51 |
| Amoxicillin | 21 | $49 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 15 | $42 |
| Levofloxacin | 19 | $26 |
Paid to pharmacies, not to this prescriber.
Other urology in Hurst
- Zvi SchiffmanHouston$17.8M
- Jose de la CerdaSan Antonio$9M
- Daniel SaltzsteinSan Antonio$5.8M
- Jose KaramHouston$5.7M
- Daniel ZainfeldSan Antonio$4.7M
- Brian MazzarellaLakeway$4.5M
- Andrew von EschenbachMontgomery$3.2M
- Raj SatkunasivamHouston$2.6M
- Alan SkolnickHouston$2.4M
- Homa PorterDallas$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.